Frias JP, Bonora E, Cox DA, et al. - According to this post hoc analysis, glycemic control was improved by increasing the dose of dulaglutide from 1.5 to 3.0 or 4.5 mg across all baseline HbA1c subgroups.

• HbA1c change from baseline and proportions of subjects achieving HbA1c < 7% at weeks 36 and 52 with dulaglutide 1.5, 3.0, or 4.5 mg across clinically relevant baseline HbA1c subgroups were investigated.

• At 36 weeks, mean HbA1c reductions were observed across all baseline HbA1c subgroups (dose [range of HbA1c change]): 1.5, 3.0, and 4.5 mg.

• Regardless of baseline HbA1c, more patients randomised to 3.0 or 4.5 mg (vs 1.5 mg) achieved HbA1c < 7% at 36 weeks; the proportion difference was greater at higher baseline HbA1c.

• At 52 weeks, similar patterns of glycemic improvement and proportions achieving HbA1c < 7% were observed.

• Between HbA1c subgroups, hypoglycemia and gastrointestinal adverse events were comparable.